FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113758797> ?p ?o ?g. }

• W2113758797 abstract "Abstract Background Treatment guidelines recommend LDL-C as the primary target of therapy in patients with hypercholesterolemia. Moreover, combination therapies with lipid-lowering drugs that have different mechanisms of action are recommended when it is not possible to attain LDL-C targets with statin monotherapy. Understanding which treatment or patient-related factors are associated with attaining a target may be clinically relevant. Methods Data were pooled from two multicenter, randomized, double-blind studies. After stabilization on simvastatin 20 mg, patients with coronary heart disease (CHD) alone and/or type 2 diabetes mellitus (T2DM) were randomized to ezetimibe 10 mg/simvastatin 20 mg (EZ/Simva) or simvastatin 40 mg. The change from baseline in low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), TC/HDL-C ratio, triglycerides, and the proportion of patients achieving LDL-C < 2.6 mmol/L (100 mg/dL) after 6 weeks of treatment were assessed, and factors significantly correlated with the probability of achieving LDL-C < 2.6 mmol/L in a population of high cardiovascular risk Italian patients were identified. A stepwise logistic regression model was conducted with LDL-C < 2.6 mmol/L at endpoint as the dependent variable and study, treatment, gender, age (≥65 years or < 65 years), as independent variables and baseline LDL-C (both as continuous and discrete variable). Results EZ/Simva treatment (N = 93) resulted in significantly greater reductions in LDL-C, TC, and TC/HDL-C ratio and higher attainment of LDL-C < 2.6 mmol/L vs doubling the simvastatin dose to 40 mg (N = 106). Study [including diabetic patients (OR = 2.9, p = 0.003)], EZ/Simva treatment (OR = 6.1, p < 0.001), and lower baseline LDL-C (OR = 0.9, p = 0.001) were significant positive predictors of LDL-C target achievement. When baseline LDL-C was expressed as a discrete variable, the odds of achieving LDL-C < 2.6 mmol/L was 4.8 in favor of EZ/Simva compared with Simva 40 mg (p < 0.001), regardless of baseline LDL-C level. Conclusion EZ/Simva is an effective therapeutic option for patients who have not achieved recommended LDL-C treatment targets with simvastatin 20 mg monotherapy. Trial Registration Clinical trial registration numbers: NCT00423488 and NCT00423579" @default.
• W2113758797 created "2016-06-24" @default.
• W2113758797 creator A5006546652 @default.
• W2113758797 creator A5060169707 @default.
• W2113758797 creator A5068223964 @default.
• W2113758797 creator A5077955682 @default.
• W2113758797 creator A5079126208 @default.
• W2113758797 date "2010-07-27" @default.
• W2113758797 modified "2023-09-26" @default.
• W2113758797 title "Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes" @default.
• W2113758797 cites W1964532888 @default.
• W2113758797 cites W1969534558 @default.
• W2113758797 cites W1985258577 @default.
• W2113758797 cites W1991158121 @default.
• W2113758797 cites W1994618005 @default.
• W2113758797 cites W1996755250 @default.
• W2113758797 cites W2000030100 @default.
• W2113758797 cites W2001375687 @default.
• W2113758797 cites W2015235485 @default.
• W2113758797 cites W2016253197 @default.
• W2113758797 cites W2025041596 @default.
• W2113758797 cites W2029158612 @default.
• W2113758797 cites W2038754854 @default.
• W2113758797 cites W2062693500 @default.
• W2113758797 cites W2066666645 @default.
• W2113758797 cites W2083734048 @default.
• W2113758797 cites W2104058454 @default.
• W2113758797 cites W2104982711 @default.
• W2113758797 cites W2115984112 @default.
• W2113758797 cites W2123341306 @default.
• W2113758797 cites W2124186024 @default.
• W2113758797 cites W2126477578 @default.
• W2113758797 cites W2126986310 @default.
• W2113758797 cites W2139277690 @default.
• W2113758797 cites W2144790234 @default.
• W2113758797 cites W2147155836 @default.
• W2113758797 cites W2149043451 @default.
• W2113758797 cites W2149166402 @default.
• W2113758797 cites W2149551498 @default.
• W2113758797 cites W2163106819 @default.
• W2113758797 cites W2163252871 @default.
• W2113758797 cites W2164551379 @default.
• W2113758797 cites W2170452015 @default.
• W2113758797 cites W2305718992 @default.
• W2113758797 cites W4238251256 @default.
• W2113758797 cites W4254405411 @default.
• W2113758797 doi "https://doi.org/10.1186/1476-511x-9-80" @default.
• W2113758797 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2918617" @default.
• W2113758797 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20663203" @default.
• W2113758797 hasPublicationYear "2010" @default.
• W2113758797 type Work @default.
• W2113758797 sameAs 2113758797 @default.
• W2113758797 citedByCount "13" @default.
• W2113758797 countsByYear W21137587972012 @default.
• W2113758797 countsByYear W21137587972014 @default.
• W2113758797 countsByYear W21137587972015 @default.
• W2113758797 countsByYear W21137587972017 @default.
• W2113758797 countsByYear W21137587972018 @default.
• W2113758797 countsByYear W21137587972019 @default.
• W2113758797 countsByYear W21137587972020 @default.
• W2113758797 crossrefType "journal-article" @default.
• W2113758797 hasAuthorship W2113758797A5006546652 @default.
• W2113758797 hasAuthorship W2113758797A5060169707 @default.
• W2113758797 hasAuthorship W2113758797A5068223964 @default.
• W2113758797 hasAuthorship W2113758797A5077955682 @default.
• W2113758797 hasAuthorship W2113758797A5079126208 @default.
• W2113758797 hasBestOaLocation W21137587971 @default.
• W2113758797 hasConcept C126322002 @default.
• W2113758797 hasConcept C134018914 @default.
• W2113758797 hasConcept C164705383 @default.
• W2113758797 hasConcept C168563851 @default.
• W2113758797 hasConcept C203092338 @default.
• W2113758797 hasConcept C2776329913 @default.
• W2113758797 hasConcept C2776839432 @default.
• W2113758797 hasConcept C2776999253 @default.
• W2113758797 hasConcept C2777180221 @default.
• W2113758797 hasConcept C2777482532 @default.
• W2113758797 hasConcept C2778163477 @default.
• W2113758797 hasConcept C2778402494 @default.
• W2113758797 hasConcept C2778657065 @default.
• W2113758797 hasConcept C2780578515 @default.
• W2113758797 hasConcept C2908647359 @default.
• W2113758797 hasConcept C555293320 @default.
• W2113758797 hasConcept C71924100 @default.
• W2113758797 hasConcept C90924648 @default.
• W2113758797 hasConcept C99454951 @default.
• W2113758797 hasConceptScore W2113758797C126322002 @default.
• W2113758797 hasConceptScore W2113758797C134018914 @default.
• W2113758797 hasConceptScore W2113758797C164705383 @default.
• W2113758797 hasConceptScore W2113758797C168563851 @default.
• W2113758797 hasConceptScore W2113758797C203092338 @default.
• W2113758797 hasConceptScore W2113758797C2776329913 @default.
• W2113758797 hasConceptScore W2113758797C2776839432 @default.
• W2113758797 hasConceptScore W2113758797C2776999253 @default.
• W2113758797 hasConceptScore W2113758797C2777180221 @default.
• W2113758797 hasConceptScore W2113758797C2777482532 @default.
• W2113758797 hasConceptScore W2113758797C2778163477 @default.
• W2113758797 hasConceptScore W2113758797C2778402494 @default.
• W2113758797 hasConceptScore W2113758797C2778657065 @default.
• W2113758797 hasConceptScore W2113758797C2780578515 @default.

• next